The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 93 results:
Author [ Title(Desc)] Type Year
Filters: Author is Anastasilakis, Athanasios D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
N
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Ballaouri I., Efstathiadou Z., et al. (2009).  No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.. Clin Endocrinol (Oxf). 70(4), 522-6.
Makras, P., Anastasilakis A. D., Polyzos S. A., Bisbinas I., Sakellariou G. T., & Papapoulos S. E. (2011).  No effect of rosuvastatin in the zoledronate-induced acute-phase response.. Calcif Tissue Int. 88(5), 402-8.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., et al. (2018).  Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.. Hormones (Athens). 17(4), 573-579.
Vachliotis, I. D., Anastasilakis A. D., Goulas A., Goulis D. G., & Polyzos S. A. (2022).  Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.. Diabetes Obes Metab. 24(9), 1702-1720.
Perakakis, N., Polyzos S. A., Yazdani A., Sala-Vila A., Kountouras J., Anastasilakis A. D., et al. (2019).  Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study.. Metabolism. 154005.
Polyzos, S. A., Anastasilakis A. D., Anagnostis P., Kita M., Arsos G., Moralidis E., et al. (2012).  Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.. Endokrynol Pol. 63(4), 312-5.
Anastasilakis, A. D., Savvides M., Polyzos S. A., Georgopoulos C., & Delaroudis S. (2010).  Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone.. J Bone Miner Metab. 28(1), 108-10.
P
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Paget's disease of bone: emphasis on treatment with zoledronic acid.. Expert Rev Endocrinol Metab. 4(5), 423-434.
Anastasilakis, A. D., Polyzos S. A., Makras P., Kampas L., Valeri R. Maria, Kyriakoulis D., et al. (2012).  Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature.. Hormones (Athens). 11(4), 419-27.
Makras, P., Polyzos S. A., Papatheodorou A., Kokkoris P., Chatzifotiadis D., & Anastasilakis A. D. (2013).  Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.. Clin Endocrinol (Oxf). 79(4), 499-503.
Polyzos, S. A., Makras P., Anastasilakis A. D., Mintziori G., Kita M., Papatheodorou A., et al. (2017).  Periostin and sclerostin levels in juvenile Paget's disease.. Clin Cases Miner Bone Metab. 14(2), 269-271.
Polyzos, S. A., & Anastasilakis A. D. (2016).  Periostin on the road to nonalcoholic fatty liver disease.. Endocrine. 51(1), 4-6.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Yavropoulou M. P., & Makras P. (2021).  Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.. Maturitas. 147, 19-25.
Polyzos, S. A., Anastasilakis A. D., Iakovou I. P., & Partsalidou V. (2010).  Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man.. Arq Bras Endocrinol Metabol. 54(6), 578-82.
Polyzos, S. A., Anastasilakis A. D., Litsas I., Efstathiadou Z., Kita M., Arsos G., et al. (2010).  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.. J Bone Miner Metab. 28(6), 706-12.
Anastasilakis, A. D., Trovas G., Balanika A., Polyzos S. A., Makras P., & Tournis S. (2020).  Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.. J Clin Densitom.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.